Press Releases

Amarantus BioSciences Retains JS Barkats in New York as Corporate & Securities Counsel

SUNNYVALE, Calif. and NEW YORK, Oct. 15, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), today announced that it has retained the legal services of JS Barkats, PLLC  ("JS Barkats") to represent the  Company as its corporate and securities counsel. Going forward, JSBarkats will represent the Company on all corporate, securities, capital markets, divestitures, partnerships, sponsorships and regulatory compliance matters. Amarantus will continue to work with Wilson, Sonsini, Goodrich & Rosati, LLP for all MANF intellectual property matters, and with Foley & Lardner, LLP on all diagnostic intellectual property matters.

"We are excited to represent Amarantus and be given the opportunity to bring value-added services to the table for our new client. Our team of experienced attorneys is impressed with the Company's proprietary technology and approach to treating Parkinson's disease and Traumatic Brain Injury," said Sunny Joseph Barkats, Founding Partner at JS Barkats. "Amarantus' corporate awareness programs, through its #C4CT concussion program and emerging relationships with professional athletes, are pioneering within development-stage biotechnology that will allow the Company to carve out a unique position for itself in the marketplace as it executes on its business strategy."

Robert Rash, the co-managing partner of the Firm in the Alabama offices added "As a CPA and a securities attorney, I am very interested in Amarantus revenue model being prosecuted through the aggregation and partnering of the Parkinson's NuroPro blood test and Alzheimer's LymPro blood test. JSBarkats believes this Company has extremely bright, talented people on its management team and the business approach is unique and innovative. Hence, we are delighted to represent Amarantus in order to assist management in maximizing the Company's value for shareholders."

About JSBarkats, PLLC:

JS Barkats, a boutique law firm headquartered in the heart of midtown-Manhattan in New York, has an experienced team of 22 attorneys with satellite offices in Alabama, Florida and Israel, as well as international affiliated offices. The firm specializes in, IPO's, APO's for public companies, SEC compliance and representation, intellectual property, licensing, corporate partnerships, tax law, commercial and securities litigation, entertainment and brand awareness.

About Amarantus BioSciences, Inc.:

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Taken together, the Company is pursuing market opportunities that could potentially represent $1B+ in annual revenues. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.


Amarantus BioSciences, Inc.

Gerald E. Commissiong


SOURCE Amarantus BioSciences, Inc.